ArticleBMJ oncology2025

Evaluating the genetic landscape of prostate cancer: new insights from BRCA1/2, ATM and CDK12 mutations.

Fumihiko Urabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.